Regulators and academics paving new paths for clinical cancer research

IBCD 2020 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA specialists endeavour to build upon the recommendations and action points decided upon at the IBCD 2018 edition.

Programme

Programme - Illustration

A panel of pathologists, clinical researchers, industry representatives, regulators and patient advocates will address burning topics such as critical issues in drug and biomarker development, comparative effectiveness research and the translation of findings of clinical trials into daily practice. The conference will also discuss and debate the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.

Read more

Registration

Would you like to participate in IBCD?

REGISTER FOR FREE

Sponsorship

Sponsorship illustration

We welcome your support for this meeting which will foster new forms of partnerships between academia, industry, regulatory, health technology assessment bodies and payers adding value to tomorrow’s personalised cancer treatments for patients in a daily practice setting.

Contact us

Scientific Committee

Roberto Salgado - EORTC

Robert Salgado, Belgium
Chair

EORTC

Luc Dirix - EORTC

Luc Dirix, Belgium

Elisa Giovannetti - EORTC

Elisa Giovanetti, Italy

NCI

Tracy Lively - NCI

Tracy Lively, USA,
Cochair

Sherry X. Yang - NCI

Sherry Yang, USA

EMA

Sinan B Sarac - EMA

Sinan B. Sarac, Netherlands,
Cochair

Jonas Bergh - EMA

Jonas Bergh, Sweden

AACR

David Solit - AACR

David Solit, USA,
Cochair

Kurt Schalper - AACR

Kurt Schalper, USA